SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL

Journal of the American College of Cardiology
Matthew A CavenderCVD-REAL Investigators and Study Group

Abstract

Prior studies found patients treated with sodium-glucose co-transporter-2 inhibitors (SGLT-2i) had lower rates of death and heart failure (HF). Whether the benefits of SGLT-2i vary based upon the presence of cardiovascular disease (CVD) is unknown. This study sought to determine the association between initiation of SGLT-2i therapy and HF or death in patients with and without CVD. The CVD-REAL (Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors) study was a multinational, observational study in which adults with type 2 diabetes were identified. Patients prescribed an SGLT-2i or other glucose-lowering drugs (GLDs) were matched based on a propensity score for initiation of an SGLT-2i. Hazard ratios (HRs) for the risk of death, HF, and HF or death in patients with and without established CVD were estimated for each country and pooled. After propensity score matching, 153,078 patients were included in each group. At baseline, 13% had established CVD. Compared with therapy using other GLDs, initiation of an SGLT-2i was associated with lower risk of death in patients with and without CVD (HR: 0.56; 95% confidence interval [CI]: 0.44 to 0.70; and HR: 0.56; 95% CI: 0.50 to 0.63, respectively). There ...Continue Reading

Citations

Jul 14, 2018·Diabetes, Obesity & Metabolism·Emanuel RaschiFabrizio De Ponti
Sep 12, 2018·Journal of Diabetes·Zachary Bloomgarden
Jul 11, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Amar AliUNKNOWN As part of The Improving Diabetes Steering Committee
Aug 29, 2019·Current Topics in Medicinal Chemistry·Ban LiuBiao Yan
Nov 27, 2019·Cardiac Failure Review·Muhammad Shahzeb Khan, Javed Butler
Apr 7, 2020·Diabetes, Obesity & Metabolism·Colin P O'Leary, Matthew A Cavender
Jul 19, 2020·Journal of Clinical Medicine·Luca De NicolaRoberto Minutolo
Sep 25, 2020·BMJ : British Medical Journal·Kristian B FilionUNKNOWN Canadian Network for Observational Drug Effect Studies (CNODES) Investigators
Dec 18, 2018·Frontiers in Cardiovascular Medicine·Devinder S DhindsaMichael D Shapiro
May 3, 2019·Journal of Diabetes·Muhammad Shahzeb Khan, Javed Butler
Jun 27, 2019·Drugs·Sohita Dhillon
Aug 30, 2019·Pharmacoepidemiology and Drug Safety·Matthew H SecrestKristian B Filion
Aug 29, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Dhiren K Patel, Jodi Strong
Sep 4, 2020·Pharmacology Research & Perspectives·Katherine N BachmannRosette J Chakkalakal
Mar 3, 2020·Frontiers in Cardiovascular Medicine·Jenny E KanterKarin E Bornfeldt
May 16, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Björn EliassonAnn-Marie Svensson
Jan 8, 2019·The Korean Journal of Internal Medicine·Hong-Mi ChoiJong-Chan Youn
Nov 28, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Viswanathan MohanJean C Mbanya
Dec 8, 2020·Journal of Diabetes and Its Complications·Vishnu GarlaLillian F Lien
Mar 5, 2021·European Journal of Preventive Cardiology·Ricardo Fontes-CarvalhoFrancesco Cosentino
Mar 10, 2021·Current Atherosclerosis Reports·Muhammad Imtiaz Ahmad, Michael D Shapiro
May 20, 2020·Trends in Molecular Medicine·Nathan O StitzielKarin E Bornfeldt
Apr 24, 2021·Expert Opinion on Drug Metabolism & Toxicology·Panagiotis-Nikolaos LalagkasAntonios Douros
May 18, 2021·International Heart Journal·Kaho ShibataHideo Fujita

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Related Papers

© 2022 Meta ULC. All rights reserved